WALTHAM, Mass.–(BUSINESS WIRE)–Nov. 4, 2020– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Stifel Virtual Healthcare Conference on Tuesday, November 17, 2020 at 1:20 p.m. ET. Jamey Mock, SVP and chief financial officer of PerkinElmer, will provide an update on... Read more
Shimadzu’s New Imaging System Enables Integrated Analysis of Both Trace Elements and Various CompoundsAdvancing Elucidation of the Mechanisms of Disease Onset and the Development of Therapeutic Drugs Read more
Addition of CRISPR and RNAi offerings to complement PerkinElmer’s life sciences and applied genomics solutions, with future opportunities to improve cell based discovery for precision medicine WALTHAM, Mass. –(BUSINESS WIRE)–Nov. 2, 2020– PerkinElmer, Inc. Read more
Latest testing strategy to increase the sample processing efficiency WALTHAM, Mass. –(BUSINESS WIRE)–Oct. 29, 2020– PerkinElmer, Inc. (NYSE: PKI) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) to allow sample pooling with PerkinElmer Read more
Thermo Fisher and Symphogen continue work to support the development of innovative cancer treatments through optimization of protein characterization and quality monitoring mass spectrometry workflows Read more
Revenue of $964.0 million; 36% reported growth; 34% organic growth GAAP EPS from continuing operations of $1.57; Adjusted EPS of $2.09 WALTHAM, Mass.–(BUSINESS WIRE)–Oct. 28, 2020– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the third quarter ended October 4, 2020. The Company reported... Read more
Thermo Fisher Scientific Expands Direct-to-Patient Clinical Trials Service Offerings End-to-end solution accelerates clinical trials with speed, convenience and quality WALTHAM, Mass., Oct. 27, 2020 /PRNewswire/ — A newly expanded Direct-to-Patient service offering supports decentralized clinical trials to minimize clinical trial length and costs while maximizing patient enrollment and participation rates. The comprehensive offering now includes... Read more